Outlook Therapeutics Inc
OTLK
NASDAQ
Biotechnology
$0.76
USD
-0.13 (-14.90%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $163.15M
Volume 104.4M
Revenue
$424,928
TTM
— YoY
Gross Margin
-46%
TTM
— YoY
Net Income
$-60.96M
TTM
-388.6%
YoY
Operating Cash Flow
$-47.05M
TTM
+26.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 1.5 | 0.0 | -1.2 | 0.1 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.4 | 0.0 | 0.0 | 0.1 |
Gross Profit | 0.0 | 1.1 | 0.0 | -1.2 | -0.0 |
Selling, General & Administrative | 8.0 | 9.7 | 0.0 | 8.6 | 9.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 12.4 | 16.8 | 0.0 | 12.2 | 14.0 |
Operating Income | -12.4 | -15.7 | 0.0 | -13.5 | -14.0 |
EBITDA | -12.4 | -15.7 | 0.0 | -13.5 | -14.0 |
Other Income / Expense | -33.9 | -4.4 | 0.0 | -9.6 | 9.6 |
Total Other Income / Expense | -34.0 | -4.4 | 0.0 | -9.6 | 9.6 |
Income Before Income Taxes | -46.4 | -20.2 | 0.0 | -23.1 | -4.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -46.4 | -20.2 | -13.3 | -23.1 | -4.5 |
Consolidated Net Income / Loss | -46.4 | -20.2 | 0.0 | -23.1 | -4.5 |
Net Income Attributable to Common Shareholders | -46.4 | -20.2 | 0.0 | -23.1 | -4.5 |
Basic EPS | -$1.50 | -$0.55 | $0.00 | -$0.38 | -$0.05 |
Diluted EPS | -$1.50 | -$0.55 | $0.00 | -$0.38 | -$0.05 |
Basic Shares Outstanding | 30.9M | 37.0M | 47.1M | 60.2M | 81.8M |
Diluted Shares Outstanding | 30.9M | 37.0M | 47.1M | 60.2M | 81.8M |